Informed clinical development programs for pipeline assets with HTA (health technology assessment) strategic insights. Informed leadership decision making over business development opportunities with access and pricing evaluations.
• Developed market access strategies for core assets, including the Orexin Agonist TAK-861 in Narcolepsy.
• Strategically informed business development deals in Neurodegeneration, Neuromuscular and Rare Disease.
• Attracted and retained talent and built a high performing team

Safeguarded Patient's timely access to Gilead's innovative treatments in HCV and HBV (Hepatitis
● and
● Viruses). Defined payer value differentiation of Epclusa and enabled payer recognition of the value of HCV elimination.
• Developed the indication strategy plan and plan of action for HCV and HBV.
• Supported flawless P&R (pricing and reimbursement) renegotiations in key markets.
• Rolled out key global deliverables cross functionally and in partnership with key markets (e.g., innovative contracting solutions, Payer Value Story, elevator pitch, objection handler, Advisory boards, Pricing policy, Evidence generation plan, Game Theory Workshops, P&R renegotiations in key markets).

Ensured timely access and reimbursement to Sanofi medicines in Rheumatology at a price reflective of value.
• Developed the Global Market Access and Pricing Strategy for the Rheumatology Franchise.
• Achieved pricing, access and reimbursement for Kevzara in rheumatoid arthritis in more than 25 markets.
• Secured positive HTA recommendations across markets, including a recognized added benefit for Kevzara by G-BA
in Germany that resulted in a higher reimbursed price.
• Informed clinical trial design and evidence generation strategy for indication expansions of giant cell arthritis,
polymyalgia rheumatica and COVID-19 through payers’ and clinicians’ insights.
• Built successful teams and unleashed full potential.

Ensured development of effective clinical trial designs and evidence generation plans to maximize the market access and pricing potential of key pipeline immunology assets.
• Provided high quality and timely strategic market access insights into Phase III head-to-head study protocols of upadacitinib in different indications, ensuring they met HTA and Payer's evidence expectations (through payer advisory boards, primary payer research and early HTA advice).
• Developed global market access and pricing strategy for late-stage assets and informed product positioning in relation to the rapidly evolving competitive landscape in immunology.
• Built target product profiles, target value propositions and emerging payer value messages for immunology assets in rheumatology, gastroenterology and dermatology.

Developed and executed the Pan European Market Access Strategy for pipeline assets in oncology. Ensured positive health technology appraisals resulting in successful P&R negotiations for Lonquex across Europe.
• Assisted countries in adapting HTA dossiers and health economic models and supported local negotiation process.
• Led cross functional market access product teams and supported access execution at local level.

Secured successful pricing and reimbursement negotiations with AIFA (Italian Medicinal agency) for new product launches and label extensions in Oncology and in Osteoporosis and ensured inclusion within regional formularies.
• Developed stakeholders' mapping and account management strategies
• Customized value dossier and health economics analysis at national and regional level
• Carried out high quality partnerships with clinicians for the generation, publication and dissemination of health economic studies at key congresses and hospital meetings.